pegylated interferon lambda + asunaprevir + ribavirin

Pegylated interferon lambda + asunaprevir + ribavirin is a combination therapy designed for the treatment of chronic hepatitis C virus (HCV) infection, particularly genotype 1. Pegylated interferon lambda is a type III interferon that signals through a distinct receptor (IL28R), leading to antiviral effects with potentially less hematologic toxicity than interferon alpha. Asunaprevir is an NS3 protease inhibitor that blocks viral replication by inhibiting HCV NS3 serine protease. Ribavirin is a nucleoside analog with broad antiviral activity, often used to enhance response rates. This combination has shown efficacy in achieving sustained virologic response, though it is associated with adverse events related to elevating liver enzymes.